Previous Article | Next Article ![]()
Infection and Immunity, October 2001, p. 5997-6003, Vol. 69, No. 10
Department of Molecular Biosciences, Adelaide
University, Adelaide, South Australia 5005, Australia,1 and GlaxoSmithKline
Biologicals, Rue de l'Institut 89, B-1330 Rixensart,
Belgium2
Received 9 April 2001/Returned for modification 7 May 2001/Accepted 6 July 2001
The need for the development of cheap and effective vaccines
against pneumococcal disease has necessitated the evaluation of common
virulence-associated proteins of Streptococcus
pneumoniae as potential vaccine antigens. In this study, we
examined the capacity of active immunization with a genetic toxoid
derivative of pneumolysin (PdB) and/or a fragment of choline binding
protein A (CbpA; also known as PspC, Hic, and SpsA) to protect
mice from intraperitoneal challenge with medium to very high doses of a highly virulent capsular type 2 pneumococcal strain, D39. The median
survival times for mice immunized with the individual protein antigens
in different adjuvant combinations were significantly longer than those
for mice that received the respective adjuvants alone. Mice immunized
with CbpA alone were significantly better protected than mice immunized
with PdB alone. Correspondingly, the median survival times for mice
that were immunized with a combination of PdB and CbpA were
significantly longer than those for mice that received PdB alone but
not significantly different from those that received CbpA alone. Mice
immunized with the protein antigens in a mixture of monophospholipid A
(MPL) and aluminium phosphate (AlPO4) adjuvants had higher
antibody titers than mice that received the antigens in
AlPO4 alone. Mice immunized with PdB in MPL plus
AlPO4 were also significantly better protected than mice
that received PdB in AlPO4 alone.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.10.5997-6003.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Protection against Streptococcus
pneumoniae Elicited by Immunization with Pneumolysin and
CbpA
*
Corresponding author. Mailing address: Department of
Molecular Biosciences, Adelaide University, Adelaide, South Australia 5005, Australia. Phone: 61-8-83035929. Fax: 61-8-83033262. E-mail: james.paton{at}adelaide.edu.au.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|